Experience the OCT difference.
Request your Abbott Sales rep today.
OCT reduced procedural complications1:
Stent expansion impacts outcomes. Achieving optimal stent expansion (MSA area ≥ 90%) is proven to reduce rates of adverse cardiac events.3 Stent underexpansion is an indicator of adverse events, such as stent thrombosis and restenosis.3
Stent thrombosis is a severe PCI complication that can lead to death or myocardial infarction.5
OCT-guided PCI reduced MACE by 28% compared to angiography2
OCT-guided PCI demonstrated comparable results to IVUS-guided PCI in TVF at 1 year.6
Routine use of intravascular imaging to guide PCI is superior to angiography and has shown to improve patient outcomes consistently in the network meta-analysis from 22 RCTs and 15,964 patients.7
Imaging guidance leads to lower risk of adverse events across efficacy and safety endpoints.7 Imaging guidance has shown a significant reduction in all-cause death (45%) and all-cause MI (25%).
45% Cardiac death
18% TV-MI
28% TLR
48% Reduction ST
25% Reduction all cause mortality
17% Reduction MI
OCT-guided PCI demonstrated 24% reduction in TLF, 39% reduction in Cardiac Death and 53% reduction in definite and probable stent thrombosis, as demonstrated in the LANCET Network Meta-Analysis7
Watch Dr. Alasnag review all imaging clinical data presented at the European Society of Cardiology (ESC) 2023.
Intravascular imaging data from over 15,000 patients solidifies the notion that intravascular imaging (IVI) should be the gold standard of care for better patient outcomes.
OCT-guided PCI vs. angio-guided PCI in complex cases
OCT-guided PCI vs. angio-guided PCI in bifurcations
OCT-guided PCI vs. IVUS-guided PCI
OCT-guided PCI vs. IVUS-guided PCI vs. angio alone
MAT-2311278 v3.0
INDICATIONS
Applies to OPTIS™ Imaging Systems and Software
The OPTIS™ Software and AptiVue™ E Series Software are intended to be used only with compatible OPTIS™ Imaging Systems.
The OPTIS™ Imaging Systems with a compatible Dragonfly™ Imaging Catheter are intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The compatible Dragonfly™ Imaging Catheters are intended for use in vessels 2.0 to 3.5 mm in diameter. The compatible Dragonfly™ Imaging Catheters are not intended for use in the left main coronary artery or in a target vessel which has undergone a previous bypass procedure.
The OPTIS™ Imaging Systems are intended for use in the catheterization and related cardiovascular specialty laboratories and will further compute and display various physiological parameters based on the output from one or more electrodes, transducers, or measuring devices. The physician may use the acquired physiological parameters, along with knowledge of patient history, medical expertise and clinical judgment to determine if therapeutic intervention is indicated.
Applies to OPTIS™ Next Imaging Systems and Software
The Ultreon™ 1.0 Software and Ultreon™ 2.0 Software are intended to be used only with compatible OPTIS™ Next Imaging Systems.
The OPTIS™ Next Imaging System with a compatible Dragonfly™ OPTIS™ Imaging Catheter or Dragonfly OpStar™ Imaging Catheter is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The Dragonfly™ OPTIS™ Imaging Catheter or Dragonfly OpStar™ Imaging Catheter is intended for use in vessels 2.0 to 3.5 mm in diameter. The Dragonfly™ OPTIS™ Imaging Catheter or Dragonfly OpStar™ Imaging Catheter is not intended for use in the left main coronary artery or in a target vessel which has undergone a previous bypass procedure.
The OPTIS™ Next Imaging Systems are intended for use in the catheterization and related cardiovascular specialty laboratories and will further compute and display various physiological parameters based on the output from one or more electrodes, transducers, or measuring devices. The physician may use the acquired physiological parameters, along with knowledge of patient history, medical expertise, and clinical judgment to determine if therapeutic intervention is indicated.
Applies to both OPTIS™ and OPTIS™ Next Imaging Systems and Software
The Dragonfly™ OPTIS™ or Dragonfly™ OpStar™ Imaging Catheters are intended for use in vessels 2.0 to 3.5 mm in diameter. The Dragonfly™ OPTIS™ or Dragonfly™ OpStar™ Imaging Catheters are not intended for use in the left main coronary artery or in a target vessel which has undergone a previous bypass procedure.
The OPTIS™ and OPTIS™ Next Imaging Systems are intended for use in the catheterization and related cardiovascular specialty laboratories and will further compute and display various physiological parameters based on the output from one or more electrodes, transducers, or measuring devices. The physician may use the acquired physiological parameters, along with knowledge of patient history, medical expertise, and clinical judgment to determine if therapeutic intervention is indicated.
CONTRAINDICATIONS
The OPTIS™ and OPTIS™ Next Integrated Systems and Mobile Systems with the usage of the OPTIS™ Software, AptiVue™ E Series Software, Ultreon™ 1.0 Software, and Ultreon™ 2.0 Software are contraindicated where introduction of any catheter would constitute a threat to patient safety. Contraindications include:
COMPLICATIONS
The following complications may occur as a consequence of intravascular imaging and catheterization procedure:
WARNINGS
PRECAUTIONS
MAT-2309288 v1.0
Stay Connected